Motesanib plus Carboplatin/Paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.
Authors
Novello, SScagliotti, G
Sydorenko, O
Vynnychenko, I
Volovat, C
Schneider, C
Blackhall, Fiona H
McCoy, S
Hei, Y
Spigel, D
Affiliation
*Department of Oncology, University of Turin, San Luigi Hospital, Turin, Italy; †Thoracic Surgery Department, Zaporizhzhya State Medical University, Zaporizhzhya, Ukraine; ‡Sumy Regional Oncology Centre, Sumy State University, Sumy, Ukraine; §Centrul de Oncologie Medicala, Iasi, Romania; ‖Central Hospital Bad Berka, Bad Berka, Germany; ¶Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; #Department of Biostatistics & Epidemiology, Amgen Inc., South San Francisco; **Department of Oncology, Amgen Inc., Thousand Oaks, CA; and ††Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN.Issue Date
2014-08
Metadata
Show full item recordAbstract
The phase 3 MONET1 study evaluated motesanib (a small-molecule inhibitor of vascular endothelial growth factor receptors) plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC). Treatment and enrollment of patients with squamous histology were permanently discontinued following higher early mortality and gross hemoptysis in those with squamous NSCLC who received motesanib. Enrollment of patients with nonsquamous histology was temporarily halted, but resumed following a protocol amendment (Scagliotti et al. J Clin Oncol. 2012;30:2829-2836). Herein, we report data from the squamous cohort.Citation
Motesanib plus Carboplatin/Paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study. 2014, 9 (8):1154-61 J Thorac OncolJournal
Journal of Thoracic OncologyDOI
10.1097/JTO.0000000000000227PubMed ID
25157768Type
ArticleLanguage
enISSN
1556-1380ae974a485f413a2113503eed53cd6c53
10.1097/JTO.0000000000000227
Scopus Count
Collections
Related articles
- International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
- Authors: Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR
- Issue date: 2012 Aug 10
- Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis.
- Authors: Kubota K, Ichinose Y, Scagliotti G, Spigel D, Kim JH, Shinkai T, Takeda K, Kim SW, Hsia TC, Li RK, Tiangco BJ, Yau S, Lim WT, Yao B, Hei YJ, Park K
- Issue date: 2014 Feb
- Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.
- Authors: Kubota K, Yoshioka H, Oshita F, Hida T, Yoh K, Hayashi H, Kato T, Kaneda H, Yamada K, Tanaka H, Ichinose Y, Park K, Cho EK, Lee KH, Lin CB, Yang JC, Hara K, Asato T, Nakagawa K
- Issue date: 2017 Nov 10
- Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.
- Authors: Blumenschein GR Jr, Reckamp K, Stephenson GJ, O'Rourke T, Gladish G, McGreivy J, Sun YN, Ye Y, Parson M, Sandler A
- Issue date: 2010 Jan 1
- A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.
- Authors: Blumenschein GR Jr, Kabbinavar F, Menon H, Mok TSK, Stephenson J, Beck JT, Lakshmaiah K, Reckamp K, Hei YJ, Kracht K, Sun YN, Sikorski R, Schwartzberg L, Motesanib NSCLC Phase II Study Investigators.
- Issue date: 2011 Sep